Human Recombinant Insulin Market to Surpass USD 47.8 Billion by 2026

The global human recombinant insulin market was valued USD 27.4 billion in 2018, and is projected to exhibit a CAGR of 7.2 percent from 2018 – 2026. Key manufacturers are engaged in launching novel human insulin portfolio and gaining regulatory approval for their insulin product portfolio. For instance, in August 2014, Eli Lilly and Company launched Jardiance (empagliflozin) as a treatment option for Type 2 diabetes patients in the US. Jardiance is a sodium glucose co-transporter-2 (SGLT2) inhibitor with Type 2 diabetes patients. In March 2016, Biocon Limited collaborated with LaboratoriosPiSA S.A de CV (PiSA) to jointly develop and sell a generic recombinant human insulin in America. Biocon expects the product to launch by 2020 in the US. In February 2018, Novo Nordisk launched Fiaspa: fast-acting mealtime insulin in the US. Fiaspa received US FDA approval and indicated to improve glycemic control in adults with type 1 and type 2 diabetes. In December 2017, the US Food and Drug Administration (FDA) approved Sanofi’s Admelog. Admelog is follow-on mealtime insulin, which helps people living with diabetes manage blood sugar levels at mealtime.

Efficient diabetes management and ease of use creates need for advancements in current solutions of both insulin and its delivery systems thereby, offering reduced patient discomfort. Glucose Responsive Insulin (GRI) or smart insulin is a novel technology for people with diabetes, which works by automatically reacting to blood sugar fluctuations in body and responds to changing blood glucose levels. The lower or higher blood sugar levels are lead to release of more or less insulin, respectively. Smart insulin decreases the number of regular blood tests required and also minimizes the number of daily dose of insulin injections. Researchers from the University of North Carolina have been working on a smart insulin patch. For instance, in 2015, researchers reported that, smart insulin patch can use a micro-needles system to automatically detect high blood glucose levels and administer insulin appropriately. Key players in the human recombinant insulin market are implementing inorganic growth strategies to develop and introduce smart insulin technology in the market. For instance, in February 2016, Eli Lilly and Company acquired Glycostasis, Inc., a startup company engaged in developing smart insulin. Eli Lilly and Company is focused on developing Glycostasis’s ‘smart insulin’ technology. – Coherent Market Insights